

Article Title

First Author^{1,*}, **Co-Author**² and **Co-Author**²

¹Laboratory X, Institute X, Department X, Organization X, City X, State XX (only USA, Canada and Australia), Country X

²Laboratory X, Institute X, Department X, Organization X, City X, State XX (only USA, Canada and Australia), Country X

Correspondence*:

Corresponding Author

Laboratory X, Institute X, Department X, Organization X, Street X, City X, State XX (only USA, Canada and Australia), Zip Code, X Country X, email@uni.edu

2 ABSTRACT

3 For full guidelines regarding your manuscript please refer to Author Guidelines
4 or **Table 1** for a summary according to article type.

5 **Keywords:** Text Text Text Text Text Text Text Text

1 INTRODUCTION

6 Text
7 Text. Text
8 Text. Text
9 Text. Text
10 Text.

2 MATERIAL & METHODS

11 Text Text Text Text Text Text Text Text Text Text Text ? Text Text Text Text Text Text Text Text Text Text
12 Text Text Text Text Text Text Text Text Text Text Text Text Text Text. ? might want to know about text text text text
13 Text Text Text Text Text Text Text Text Text Text Text Text Text. (?) might want to know about text text text text
14 Text
15 Text Text Text Text Text Text Text Text Text Text Text Text Text. ? might want to know about text text text text ?

16 Please note that large tables covering several pages cannot be included in the final PDF for formatting
17 reasons. These tables will be published as supplementary material on the online article abstract page at the
18 time of acceptance. The author will notified during the typesetting of the final article if this is the case. A
19 link in the final PDF will direct to the online material.

20 2.1 Original Research Articles, Clinical Trial Articles, and Technology Reports

21 For Original Research Articles, Clinical Trial Articles, and Technology Reports the section headings
22 should be those appropriate for your field and the research itself. It is recommended to organize your
23 manuscript in the following sections or their equivalents for your field:

Table 1. Maximum size of the Manuscript

	Abstract max. length (incl. spaces)	Figures or tables	Manuscript max. length
Clinical Case Study Clinical Trial Hypothesis and Theory Methods Original Research Review Technology Report	2000 characters	15	12000 words
Focused Review	2000 characters	5	5000 words
CPC	1250 characters	6	2500 words
Perspective Mini Review	1250 characters	2	3000 words
Data Report	None	2	3000 words
Classification	1250 characters	10	2000 words
Editorial	None	None	1000 words
Frontiers Commentary General Commentary Book review	None	1	1000 words
Opinion Specialty Grand Challenge Field Grand Challenge	None	1	2000 words

- 24 • Introduction: Succinct, with no subheadings.
- 25 • Materials and Methods: This section may be divided by subheadings. This section should contain
26 sufficient detail so that when read in conjunction with cited references, all procedures can be repeated.
- 27 • Results: This section may be divided by subheadings. Footnotes should not be used and have to be
28 transferred into the main text.
- 29 • Discussion: This section may be divided by subheadings. Discussions should cover the key findings
30 of the study: discuss any prior art related to the subject so to place the novelty of the discovery in
31 the appropriate context; discuss the potential short-comings and limitations on their interpretations;
32 discuss their integration into the current understanding of the problem and how this advances the
33 current views; speculate on the future direction of the research and freely postulate theories that could
34 be tested in the future.

35 Please note that the Material and Methods section can be placed in any of the following ways: before
36 Results, before Discussion or after Discussion.

37 **2.2 Clinical Case Studies**

38 For Clinical Case Studies the following sections are mandatory:

- 39 • Introduction: Include symptoms at presentation, physical exams and lab results.

Table 2. Resolution Requirements for the figures

Image Type	Description	Format	Color Mode	Resolution
Line Art	An image composed of lines and text, which does not contain tonal or shaded areas.	TIFF, JPEG	RGB, Bitmap	900 - 1200 dpi
Halftone Combination	A continuous tone photograph, which contains no text. Image contains halftone + text or line art elements.	TIFF, EPS, JPEG TIFF, JPEG	RGB, Grayscale RGB, Grayscale	300 dpi 600 - 900 dpi

- 40 • Background: This section may be divided by subheadings. Include history and review of similar cases.
- 41 • Results: This section may be divided by subheadings. Include diagnosis and treatment.
- 42 • Concluding Remarks

3 RESULTS

43 3.1 Figures

44 Frontiers requires figures to be submitted individually, in the same order as they are referred to in the
 45 manuscript. Figures will then be automatically embedded at the bottom of the submitted manuscript. Kindly
 46 ensure that each table and figure is mentioned in the text and in numerical order. Permission must be
 47 obtained for use of copyrighted material from other sources (including the web). Please note that it is
 48 compulsory to follow figure instructions. Figures which are not according to the guidelines will cause
 49 substantial delay during the production process.

50 **Table 2** shows the resolution requirements for the figures. The figures must be legible:

- 51 1. The smallest visible text is no less than 8 points in height, when viewed at actual size.
- 52 2. Solid lines are not broken up.
- 53 3. Image areas are not pixelated or stair stepped.
- 54 4. Text is legible and of high quality.
- 55 5. Any lines in the graphic are no smaller than 2 points width.
- 56 6. The actual size of the figure must be of at least 8.5 cm.

57 3.2 Nomenclature

- 58 • The use of abbreviations should be kept to a minimum. Non-standard abbreviations should be avoided
 59 unless they appear at least four times, and defined upon first use in the main text. Consider also giving
 60 a list of non-standard abbreviations at the end, immediately before the Acknowledgments.
- 61 • Gene symbols should be italicized; protein products are not italicized.
- 62 • Chemical compounds and biomolecules should be referred to using systematic nomenclature, preferably
 63 using the recommendations by IUPAC.
- 64 • We encourage the use of Standard International Units in all manuscripts.
- 65 • To take part in the Resource Identification Initiative, please cite antibodies, genetically modified
 66 organisms, software tools, data, databases and services using the corresponding catalog number and
 67 RRID in your current manuscript. For more information about the project and for steps on how to
 68 search for an RRID, please click here.

$$\sum x + y = Z \quad (1)$$

4 DISCUSSION

69 Text
70 Text Text Text Text. Additional Requirements:

71 4.1 Corrections

72 If you need to communicate important changes to a published article please submit a General Commentary.
73 Submit the article with the title Corrigendum: Original Title of Article.

74 4.2 Commentaries on Articles

75 At the beginning of your Commentary, please provide the citation of the article commented on. Rebuttals
76 may be submitted in response to Commentaries; our limit in place is one commentary and one response.
77 Rebuttals should also be submitted as General Commentary articles.

78 4.3 Human Search and Animal Research

79 All experiments on live vertebrates or higher invertebrates must be performed in accordance with relevant
80 institutional and national guidelines and regulations. In the manuscript, authors must identify the committee
81 approving the experiments and must confirm that all experiments conform to the relevant regulatory
82 standards. For manuscripts reporting experiments on human subjects, authors must identify the committee
83 approving the experiments and must also include a statement confirming that informed consent was
84 obtained from all subjects. In Original Research Articles and Clinical Trial Articles these statements should
85 appear in the Materials and Methods section.

86 4.4 Clinical Trial Registration

87 Clinical trials should be registered in a public trials registry in order to become the object of a publication
88 at Frontiers. Trials must be registered at or before the start of patient enrollment. A clinical trial is defined
89 as "any research study that prospectively assigns human participants or groups of humans to one or more
90 health-related interventions to evaluate the effects on health outcomes."(www.who.int/ictrp/en). A list of
91 acceptable registries can be found at www.who.int/ictrp/en and www.icmje.org.

92 4.5 Inclusion of Proteomics Data

93 Authors should provide relevant information relating to how the peptide/protein matches were undertaken,
94 including methods used to process and analyze data, false discovery rates (FDR) for large-scale studies
95 and threshold or cut-off rates for peptide and protein matches. Further information could include software
96 used, mass spectrometer type, sequence database and version, number of sequences in database, processing
97 methods, mass tolerances used for matching, variable/fixed modifications, allowable missed cleavages, etc.

98 Authors should provide as supplementary material information used to identify proteins and/or peptides.
99 This should include information such as accession numbers, observed mass (m/z), charge, delta mass,
100 matched mass, peptide/protein scores, peptide modification, miscleavages, peptide sequence, match rank,
101 matched species (for cross species matching), number of peptide matches, ambiguous protein/peptide
102 matches should be indicated, etc. For quantitative proteomics analyses authors should provide information

103 to justify the statistical significance including biological replicates, statistical methods, estimates of
104 uncertainty and the methods used for calculating error.

105 For peptide matches with biologically relevant post-translational modifications (PTM) and for any protein
106 match that has occurred using a single mass spectrum, authors should include this information as raw data,
107 annotated spectra or submit data to an online repository (recommended option). Authors are encouraged to
108 submit raw or matched data and 2-DE images to public proteomics repositories. Submission codes and/or
109 links to data should be provided within the manuscript.

110 4.6 Data Sharing

111 Frontiers supports the policy of data sharing, and authors are advised to make freely available any materials
112 and information described in their article, and any data relevant to the article (while not compromising
113 confidentiality in the context of human-subject research) that may be reasonably requested by others for
114 the purpose of academic and non-commercial research. In regards to deposition of data and data sharing
115 through databases, Frontiers urges authors to comply with the current best practices within their discipline.

DISCLOSURE/CONFLICT-OF-INTEREST STATEMENT

116 The authors declare that the research was conducted in the absence of any commercial or financial
117 relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

118 The statement about the authors and contributors can be up to several sentences long, describing the tasks
119 of individual authors referred to by their initials and should be included at the end of the manuscript before
120 the References section.

ACKNOWLEDGMENTS

121 Text
122 Text Text Text Text Text. Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text
123 Text Text Text Text Text Text Text Text Text Text.

124 *Funding:* Text Text Text Text Text Text Text Text.

SUPPLEMENTAL DATA

125 Supplementary Material should be uploaded separately on submission, if there are Supplementary Figures,
126 please include the caption in the same file as the figure. LaTeX Supplementary Material templates can be
127 found in the Frontiers LaTeX folder

128 Text
129 Text Text Text Text Text.

FIGURES



Figure 1. Enter the caption for your figure here. Repeat as necessary for each of your figures